Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ: RXRX )

10.53 +2.03 (+23.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
3 AI Drug Discovery Stocks to Watch
The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Find out why analysts have such high expectations for these stocks. 
Via The Motley Fool
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Where Will Recursion Pharmaceuticals Be in 3 Years?
This biotech could still be a long way from having a drug on the market in 2026. 
Via The Motley Fool
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street
Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months. 
Via The Motley Fool
Analyst Expectations for Recursion Pharmaceuticals's Future
Via Benzinga
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
These biotech stocks to buy and hold offer tremendous upside blending long-term potential with healthcare advances. 
Via InvestorPlace
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
The famous growth investor has been making some interesting stock moves lately. 
Via The Motley Fool
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
Both businesses have a lot to prove. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
3 Clever Tricks to Find Winning Biotech Stocks
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
AI Bubble Stocks Deflating, Down 14% So Far In August
13 artificial intelligence and related stocks have dramatically outpaced the sector in general since the AI&R bubble began to inflate at the end of April. MTD, however, they have declined 13.6%, on... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M
Via Benzinga
Topics Earnings
Exposures Financial
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead
Via Benzinga
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing. 
Via InvestorPlace
3 Green Flags for Biotech Stocks in 2023 and Beyond
The industry is changing rapidly, and for the better. 
Via The Motley Fool
Cathie Wood's Ark Invest Continues To Sell Shopify Shares Amid Q2 Ripples
Via Benzinga
Cathie Wood's Ark Invest Buys $16M Worth Of Shares Of Flying Taxi Company Archer Aviation — Sells Shopify Stock Worth Millions
Via Benzinga
These 9 AI Stocks Are Up 95%, On Average, Since End Of April
Nine artificial intelligence and AI-related stocks, with market caps in excess of $2B, have advanced by +60% since the bubble began to develop at the end of April into early May, with an average... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Every AI Stock Cathie Wood Owns, Ranked From Best to Worst
You can find some great AI investment opportunities by looking at the stocks in Wood's Ark Invest portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Things About Recursion Pharmaceuticals That Smart Investors Know
Until it can get some recurring revenue going, it'll be a risky stock to buy. 
Via The Motley Fool
3 AI Stocks You’ll Regret Not Buying Soon
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. 
Via InvestorPlace
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
Via Benzinga
2 Healthcare AI Stocks That Could Go Parabolic
Shares of Recursion Pharmaceuticals and GE Healthcare are both up sharply so far this year. 
Via The Motley Fool
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.